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Abstract
Background: Bacterial vaginosis (BV), an alteration of vaginal flora involving a decrease in Lactobacilli and
predominance of anaerobic bacteria, is among the most common cause of vaginal complaints for women of
childbearing age. It is well known that BV has an influence in acquisition of certain genital infections. However,
association between BV and cervical human papillomavirus (HPV) infection has been inconsistent among studies.
The objective of this meta-analysis of published studies is to clarify and summarize published literature on the
extent to which BV is associated with cervical HPV infection.
Methods: Medline and Web of Science were systematically searched for eligible publications until December 2009.
Articles were selected based on inclusion and exclusion criteria. After testing heterogeneity of studies, meta-
analysis was performed using random effect model.
Results: Twelve eligible studies were selected to review the association between BV and HPV, including a total of
6,372 women. The pooled prevalence of BV was 32%. The overall estimated odds ratio (OR) showed a positive
association between BV and cervical HPV infection (OR, 1.43; 95% confidence interval, 1.11-1.84).
Conclusion: This meta-analysis of available literature resulted in a positive association between BV and uterine
cervical HPV infection.
Background
Bacterial vaginosis (BV) is the most prevalent cause of
abnormal vaginal discharge, affecting women of repro-
ductive age [1]. This infestation is characterized by a
loss of indigenous (hydrogen peroxide-producing) Lacto-
bacillus-predominant vaginal microflora, and a concur-
rent massive overgrowth of anaerobic bacteria. The
most common include Gardnerella vaginalis, Mobilun-
cus species, Prevotella species, Mycoplasma hominis and
Atopobium vaginae [2]. At least 50% of patients have no
symptoms [3]. In the other half, it most often manifests
clinically as a thin homogenous vaginal discharge, a
vaginal pH of more than 4.5, presence of ‘clue cells’, and
an amine odour after addition of 10% of potassium
hydroxide [1,2].
The etiopathogenesis of this condition remains subject
of debate. Some risk factors have been associated with
BV, including cigarette smoking, use of intrauterine
devices, frequent vaginal douches, multiple sexual part-
ners, early age at first intercourse, and black ethnicity
[4,5]. BV has been shown to increase the risk of obste-
tric and gynaecologic complications such as preterm
labour and delivery, chorioamnionitis, post-caesarean
endometritis, postabortion pelvic inflammatory disease,
and cervicitis [6,7]. Moreover, BV has been associated
with many sexually transmitted infections (STIs), includ-
ing infection with Chlamydia trachomatis, Neisseria
gonorrhoeae, HSV-1 and 2, and an increased risk of HIV
acquisition [4,8,9]. The leading hypothesis concerning
these associations is that absence of protective lactoba-
cilli increases biological susceptibility of acquiring an
STI upon exposure. However, the temporal nature of
the association between BV and acquisition of STIs
remains an ongoing discussion. Although there is a
large bulk of evidence favouring the plausibility that BV
also incurs an elevated risk for human papillomavirus
(HPV) acquisition, this remains a matter of debate.
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It is well known that infection with oncogenic HPV, a
sexually transmitted DNA virus, is the central etiological
agent in the development of cervical cancer. Persistent
HPV infection is a prerequisite for progression to high-
grade lesions [10]. However, few HPV infections persist
and progress to cervical cancer [11]. The vast majority
cause no or only mild cytological abnormalities that
may go undetected and regress to normalcy [11]. It is
unknown why high risk HPV infection is cancerous in
some women whereas in others it is eradicated. Indivi-
dual differences in immunological defence may be one
explanation [12]. Local cervical factors may determine
the outcome of HPV. For this reason, there is a lot of
interest in studying factors predisposing towards acqui-
sition and persistence of this infection.
In contrast with cervical HPV infection, BV is asso-
ciated with major changes in the vaginal environment.
Because women with BV possess a Lactobacillus-poor
flora, their changes in the vaginal ecosystem may
provide biological plausibility for an increased risk or
reactivation of HPV infection. Little is known about how
the changed vaginal milieu in BV influences mucosal sus-
ceptibility for HPV, or vice versa, how infection with
STIs in general influences the vaginal environment. The
magnitude of association between BV and HPV has var-
ied in epidemiological studies and remains controversial,
yielding conflicting results and ranging from absence of
any association [13] to a clear positive relationship [14].
To examine this controversial literature in more detail,
a meta-analysis of available literature on the association
between BV and cervical HPV infection was conducted.
Estimates of association between BV and HPV are pre-
sented for HPV prevalence studies and analyzed for
publication bias and heterogeneity.
Methods
Literature search
Relevant studies on association between BV and HPV
infection were identified through an extensive search
of Medline, based on the following keywords: ‘bacterial
vaginosis’, ‘bacterial infections or vaginitis’, ‘BV’, ‘Gard-
nerella’, and ‘dysbacteriosis ’, in combination with
‘human papillomavirus’, ‘papillomavirus infections’,
‘HPV’ or ‘cervical screening’. This search yielded 349
different published articles. Web of Science was further
searched using the same strings, and yielding a total of
115 different publications. Only one additional eligible
article was found beyond the Medline search [15].
Studies that addressed the relationship between BV
and cervical HPV infection were reviewed for prede-
fined eligibility criteria. Two authors independently
reviewed and evaluated critically all studies for inclu-
sion (EG and DVB). Figure 1 summarizes the study
selection process.
Eligible studies needed a clear description of diagnos-
tic methods used for detecting both BV and HPV.
There was no restriction in study design. Articles were
included if they either reported odds ratios and corre-
sponding 95% confidence intervals (CI) representing the
magnitude of association between BV and cervical HPV
infection, or presented data for calculation.
Reference lists of relevant papers and reviews were
examined to identify further articles. Studies were limited
to those written in English. We stopped our literature
search in December 2009, but there was no publication
starting-date limitation. The meta-analysis was restricted
to original articles (no expert opinions, editorials or
reviews). Conference abstracts and other unpublished
articles were excluded, as these could not be systemati-
cally reviewed and data could not be verified. This meta-
analysis was based on the Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) guidelines [16].
Data abstraction and selection criteria
For each study, the following data were extracted: first
author, year of publication, country where the study was
conducted, study design, number of cases enrolled,
study population, age range of participants, method of
HPV diagnosis and HPV prevalence, BV diagnostic cri-
teria, and BV prevalence.
Participants were categorized in four groups: women
referred to colposcopy clinic because of an abnormal
Pap-smear (referred), women attending family planning/
obstetrics and gynaecology clinics (attendees), screening
population, and mixed patient groups (referred, atten-
dees and screened). In most studies, pregnancy was an
exclusion criterion. Only one study included pregnant
women [14]. Another study enrolled HIV positive and
high-risk HIV uninfected women [17].
BV prevalence was recorded as an estimate of BV in
the study population. Diagnostic criteria for BV included
Nugent’s scoring system, Amsel clinical criteria, modi-
fied Amsel criteria, and presence of clue cells. In
Nugent’s scoring system (BV when score ≥ 7), the most
accurate method, Gram-stained vaginal smears are
assessed for average number of bacterial morphotypes
seen per oil immersion field (magnification 100 times).
Briefly, large gram-positive rods (Lactobacilli) were
scored inversely from 0 to 4, small Gram-variable or
gram-negative rods (Gardnerella and Bacteroides spp)
from 0 to 4, and curved gram-variable rods (typically
Mobiluncus spp) scored from 0 to 2 [3]. Amsel criteria
define BV as presence of any three of the following
characteristics: [1] homogeneous white grey discharge
that sticks to the vaginal walls; [2] vaginal fluid pH >
4.5; [3] release of fishy amine odour from vaginal fluid
when mixed with 10% potassium hydroxide (positive
whiff test); and [4] clue cells visible on wet mount
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microscopy [3]. Modification of Amsel criteria included
diagnosing BV when only two of these four elements
were present (Peters et al. [18] used clue cells and posi-
tive whiff test). Diagnosing BV only through presence of
clue cells on wet smear or more than 20% clue cells on
Papanicolaou smear was also considered an inclusion
criteria, since this is confirmed by previous studies to be
an accurate method and good predictor for BV [19].
Studies eligible for inclusion detected cervical HPV
infection with Polymerase Chain Reaction (PCR) or
Fluorescent In Situ Hybridization (FISH). Koilocytosis
was not considered specific enough for HPV detection.
A list of studies included in the analysis and a digest of
information extracted is given in Table 1.
Statistical analysis
Meta-analysis was conducted for twelve studies that fulfil
the above-reported criteria [13-15,17,18,20-26], using
packages for STATA provided by Sterne et al. [27]. Odds
ratios and their respective standard errors were calculated
from the provided raw data. For the remaining studies,
crude odds ratios and standard errors as reported in the
article were used [17,24]. The resulting set of odds ratios
were combined into a summary estimate of the association
between BV and HPV using the random effects model of
DerSimonian and Laird [28] and results were visualised in
a forest plot. Evidence of publication bias was ruled out by
funnel plot [29] and statistically evaluated for asymmetry
using the Begg rank correlation [30]. Homogeneity of
effects across studies was assessed using Cochran’s Q test
[31] and quantified by Higgins and Thompson’s I2 [32].
Relative influence of different studies was evaluated by
estimating the combined odds ratio after omitting one
study at a time. Cumulative analysis, in which studies were
added in order of descending variance on odds ratios, was
done to rule out a potential small-study effect.
Results
Study identification and description
Initial search gave rise to 406 unduplicated articles. Titles
and abstracts were reviewed, and 51 out of 406 articles
were considered of interest. These were retained for
Figure 1 Flow-chart of article selection for inclusion in meta-analysis BV - HPV.
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detailed evaluation, and 12 were finally retrieved for statisti-
cal analysis (Figure 1). Reasons for exclusion in the last step
of our search strategy included: studies using koilocytosis as
criterion for HPV detection [33-36], studies not describing
their methodology of diagnosis [37,38], and studies using
presence of Gardnerella vaginalis [39,40] or Grade II vagi-
nal flora (according to Schröder et al.) [41] to diagnose BV.
Twelve eligible articles were identified, including a
total of 6,372 women. These studies reported thirteen
different estimates of association between BV and HPV
prevalence for twelve study populations. One study
reported estimates using two different methods of BV
diagnosis, i.e. Amsel and presence of clue cells [20]. The
estimate based on the most stringent method (Amsel)
was used for meta-analysis.
Most studies using adjusted odds ratios (AOR) did not
describe clearly potential confounders and methods
used. Consequently, the reported AOR could not be
compared between studies. Therefore, where possible,
raw data were retrieved for statistical analysis. Two
studies did not mention raw data, hence only the reported
crude odds ratios could be used [17,24]. One study was
excluded [42], because only crude and adjusted relative
risks were described (crude RR, 1.20; 95% CI, 0.89-1.62;
RR adjusted for ethnicity, sexual partners in past year and
douching in past month, 1.08; 95% CI 0.82-1.42).
Studies included in the meta-analysis comprised ten
cross-sectional studies [13-15,17,18,20-22,25,26] and two
follow up studies [23,24]. One study measured addi-
tional incidence rates (defined as recruiting HPV-nega-
tive women and prospectively measuring incident HPV
infection), but only baseline data was extracted for
meta-analysis (odds ratio for incidence study, 1.41; 95%
CI 1.25-1.59) [17].
Regarding geographical location, four studies were
conducted in low-income [14,15,21,25] and eight in
developed countries [13,17,18,20,22-24,26]). Five studies
were conducted in Europe [13,18,20,26,43], three in the
United States [17,23,24], three in South-America
[14,15,21], and one in Asia [25]. Eligible studies
performed in Africa were not found.
Diagnosis and prevalence of bacterial vaginosis
BV was diagnosed either using clinical Amsel or modi-
fied Amsel criteria in seven out of twelve studies
[14,18,20,23,25,26,43], Nugent’s score in three out of
twelve studies [17,21,24] and presence of clue cells in
two out of twelve studies [13,15]. BV prevalence ranged
from 3.0% in sexually active university students ranged
18-24 years in the USA [23] to 47.2% in sexually active
women ranged 13-19 years in the USA attending a pri-
mary care clinic [24]. Large variation in reported
Table 1 Characteristics of the selected studies included in the meta-analysis BV - HPV
Year of
publication
Authors Country Study
Design
Nr cases
enrolled
Participants Age range
(Years)
HPV
Diag
HPV Prev
(%)
BV
Diag
BV Prev
(%)
1995 Peters et al
[18]
Netherlands CS 280 referred 20 - 66 PCR 71.1 Mod
Amsel
20.0
1997 Sikström et al
[20]
Sweden CS 972 attendees - FISH 6.8 Amsel 13.0
2001 Castle et al
[21]
Costa Rica CS 8582 screened - PCR 59.6 Nugent 37.8
2003 Mao et al[23] USA FU 516 screened 18 - 24 PCR 22.8 Amsel 3.0
2003 Boyle et al
[22]
UK CS 379 attendees 16 - 58 PCR 21.1 Amsel 30.9
2004 da Silva et al
[14]
Brazil CS 52 attendees 15 - 35 PCR 50.0 Amsel 34.6
2005 Watts et al
[17]*
USA CS 2229 attendees (HIV and
high-risk)
- PCR 56.1 Nugent 43.7
2005 Samoff et al
[24]*
USA FU 151 attendees 13 - 19 PCR 53.5 Nugent 47.2
2008 Figueiredo et
al[15]
Brazil CS 228 referred - PCR 84.2 Clue
cells
17.0
2009 Verteramo et
al[26]
Italy CS 857 attendees 17 - 58 PCR 31.0 Amsel 6.3
2009 Nam et al[25] South-
Korea
CS 510 referred - PCR 69.1 Amsel 11.0
2009 Rahkola et al
[13]
Finland CS 328 mix 18 - 69 PCR 53.3 Clue
cells
15.2
** Prevalence and incidence study.
Abbreviations: HPV = Human Papillomavirus; BV = Bacterial vaginosis, PCR = Polymerase Chain Reaction, FISH = Fluorescent In Situ Hybridization, CS = Cross-
sectional study, FU = Follow-up study, Diag = diagnosis, Prev = Prevalence.
Participants: referred (women referred to colposcopy clinic because of abnormal Pap-smear), attendees (women attending family planning or obstetrics and
gynaecology clinics), screened (population sample, screening), mix (referred, attendees and/or screened).
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prevalence figures can be attributed to differing recruit-
ment strategies, inclusion of different patient popula-
tions, and variation in diagnostic criteria. Pooled BV
prevalence was 31.2% (95% CI, 12.3%-51.6%).
Prevalence of BV using Nugent’s criteria was consis-
tently higher as opposed to studies using clinical Amsel
criteria or presence of clue cells, ranging from 37.8 to
47.2%. Prevalence of BV using Amsel criteria and pre-
sence of clue cells ranged from 3.0 to 34.6% and from
15.2 to 20.2% respectively. Pooled prevalence of BV in
low-income countries was 35.8% (95% CI, 20.8%-50.9%)
while in developed countries it was 24.8% (95% CI,
12.4%-37.2%).
Bacterial vaginosis - cervical human papillomavirus
association
Analysis of the association between BV and cervical
HPV infection shows that HPV prevalence is signifi-
cantly higher in BV positive women in only three out of
twelve studies compared to women without BV
[14,17,23]. Figure 2 represents reported odds ratios with
their 95% CI for the likelihood of detecting cervical
HPV in presence of BV, weight given to each study in
random effects model, and combined odds ratio with
95% CI. Odds ratios in different studies ranged from
0.60 [13] to 6.42 [14]. The combined odds ratio for
included cross-sectional studies was 1.43 (95% CI, 1.11-
1.84, p = 0.005), indicating a positive association
between BV and cervical HPV infection.
A funnel plot confirmed lack of obvious publication
bias as no clear asymmetry could be detected (Figure 3).
Also Begg’s rank correlation test could not detect a
significant publication bias (z = 0.82, p > 0.05). Included
studies showed clear heterogeneity according to
Cochran’s Q test (c2 = 28.8, p < 0.01). About 60% of the
total variation could be explained by heterogeneity
between samples (I2 = 60.8). Two studies [14,15]
reported higher odds ratios than can be expected in a
Figure 2 Forest plot of estimates of association between bacterial vaginosis and cervical human papillomavirus infection. Studies are
identified by references. Each study is represented by a black square and a horizontal line, which corresponds to the estimate (ES) and 95%
confidence interval (CI) of odds ratios. Area of black squares reflects weight of study in the meta-analysis.
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homogeneous set of studies (figure 2). Substantial differ-
ences in reported odds ratios among other studies form
an extra indication for existing heterogeneity.
Cumulative meta-analysis showed that small-study
effects are unlikely to have an impact on the combined
odds ratio (Figure 4). Studies with the largest standard
error on their odds ratio have also a higher combined
estimate [14,15]. However, this effect is only visible for
two studies. In general, evolution of the combined odds
ratio is stable. Moreover, two studies with an odds ratio
lower than one are among the smallest in this analysis.
Discussion
To our knowledge, this review and meta-analysis with
over 6,000 women is the first systematic evaluation of
association between BV and cervical HPV infection.
Although BV enhances acquisition of certain STIs, its
relationship to cervical HPV infection is still an issue of
controversy. Our results show evidence of a positive
association between these two very common conditions,
with an overall estimated odds ratio of 1.43.
Several hypotheses have been postulated, supporting
this association. In BV-negative women, hydrogen per-
oxide-producing lactobacilli dominate the vaginal micro-
flora and are part of the main defence mechanisms [1].
Loss of these protective micro-organisms and other
changes in the vaginal milieu, related to BV, could facili-
tate survival of other sexually transmitted agents and are
risk factors for developing vaginal infections. It is well
recognised that BV renders women vulnerable to acqui-
sition of Neisseria gonorrhoeae, Chlamydia trachomatis,
HSV-1 and 2, and HIV [8,9,42]. Moreover, BV has been
associated with a reduction in vaginal fluid levels of
secretory leukocyte protease inhibitor (SLPI), able to
block HIV infection in vitro [44]. It has been documen-
ted that BV propagates viral replication and vaginal
shedding of HSV, thereby further enhancing spread of
this STI [45].
Another hypothesis proposes that mucin-degrading
enzymes are increased in vaginal fluid of women with
BV. These enzymes, like sialidases, play a role in degra-
dation of the gel layer coating the cervical epithelium,
causing micro-abrasions or alterations of epithelial cells.
The team of Briselden demonstrated positivity for siali-
dases in 84% of BV-positive women [46]. Such enzymes
may promote virulence through destroying the protec-
tive mucosa barrier and hence increase susceptibility to
cervical HPV infection by facilitating adherence, inva-
sion and eventually incorporation of HPV oncogenes
into the genome of cells of the transformation zone.
Abnormal vaginal microflora could also be implicated in
maintenance of subclinical HPV. Furthermore, changes
in cervico-vaginal milieu resulting from co-infections
may exert an influence on the natural history of cervical
HPV infection.
It is also possible that BV is a cofactor involved in acqui-
sition or reactivation of HPV infection by affecting immu-
nological balance within the cervical tissue as a result of
changes in production of factors, such as cytokines (inter-
leukin-1ß, interleukin-10) [47]. Mucosal immune system
activation represents a critical response against micro-
organisms colonizing the reproductive tract. Neutrophil
recruitment and activation is considered the main innate
Figure 3 Funnel plot to assess publication bias. The full circles
represent the 12 included study estimates of association between
BV and prevalent cervical HPV infection. The size of association of
each study is plotted on the horizontal axis, against the standard
error on the vertical axis (on logarithmic scale). The vertical line in
the funnel plot indicates the fixed-effects summary estimate, while
the sloping lines indicate the expected 95% confidence intervals for
a given standard error.
Figure 4 Cumulative meta-analysis to evaluate small-study
effect. Studies are ordered according to descending variance on
odds ratios. The vertical line indicates the no-association line (OR
1.0). Each study is represented by a horizontal line, corresponding to
the OR (or estimates ES) and symmetric 95% CI.
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immune response against microbial and viral infections of
vaginal mucosa [47]. Women harbouring clue cells show
no inflammatory signs and neutrophils are typically rela-
tively absent in BV smears subjected to microscopy [15].
Enzymes produced by anaerobic bacteria involved in the
pathogenesis of BV can potentially alter immune signals
and promote degradation of host factors, rendering
women more susceptible of acquiring HPV.
These results, however, should be interpreted in light
of a number of methodological limitations. The analysis
suffers from the fact that most included studies had a
cross-sectional design, where data on prevalence of BV
and HPV infection were gathered simultaneously,
instead of over time. Therefore this analysis is liable to
reverse causation bias that would result from HPV
infected women being more likely to acquire BV. This
disadvantage prohibits concluding that BV increases risk
of HPV acquisition or that there is a causal relationship.
The sequence of infection is unknown and only a follow
up study can determine which condition facilitates the
other. In an incidence study by Watts et al., BV was sig-
nificantly associated with detection of new HPV infec-
tion at follow-up visit (OR, 1.41; 95% CI 1.25-1.59) [17].
Association between BV and HPV persisted even after
adjustment for number of sexual partners, suggesting
that women with BV may be more susceptible for HPV
and not simply because of shared risk factors. In con-
trast, another longitudinal study performed a time-lag
analysis to evaluate which condition preceded the other
[23]. The result suggested a temporal relationship,
where BV was found to occur simultaneously with or
after HPV infection, rather than ante-dating acquisition
of HPV. Perhaps cervical HPV infection may favour
changes in the vaginal milieu that enhances develop-
ment of BV.
The question remains whether BV and cervical HPV
infection are simply related because there is a biologic
interaction between them, or because both occur fre-
quently in sexually active women. A positive correlation
between BV and HPV might be explained by the fact
that sexual risk behaviour and promiscuity are found
more often in women with BV than in comparison
groups. Role of sexual transmission in causing or pro-
moting BV continues to be a topic of debate, as e.g.
highlighted by data in lesbians, who have a high preva-
lence of BV [48]. Although not considered an STI in its
usual sense (e.g. treatment of the sexual partner has no
effect on frequency or relapses), the epidemiological
profile of BV mirrors an STI [49]. HPV is known to be
one of the most common STIs, thus concerns regarding
confounding by sexual behaviour certainly remain.
A number of variables are contributing to observed
heterogeneity. Most prominent, prevalence of BV varied
according to the population studied. Various social
habits and ethno-geographical risk factors may explain
the wide BV prevalence range observed (3%-47.2%). It is
well recognized that prevalence of BV in African women
is among the highest worldwide [1]. This meta-analysis
did not include studies conducted in Africa. Considering
the high prevalence of BV in this continent, it would be
very interesting to evaluate the association between BV
and cervical HPV infection in African women, since we
may expect a more pronounced effect. Our unpublished
data of a cross-sectional study including 820 HIV-nega-
tive female sex workers in Mombasa (Kenya) confirms
this. In multivariate logistic regression, controlled for
other STIs and behavioural characteristics, borderline
significance was found between BV and high-risk HPV
infection (AOR, 1.72; p = 0.06).
Technical biases (e.g. collection of specimen), subjec-
tivity, sensitivity and specificity of diagnostic methods
are also attributing to detected heterogeneity.
HPV detection methods varied among included studies (e.
g. FISH is less sensitive compared to PCR) and also distri-
bution of HPV viral genotypes differed largely. However,
high-risk genotypes 16 and 18 present in prophylactic
vaccines were (when mentioned) always included.
Further, this meta-analysis was limited to that of pub-
lished studies, which could have caused publication bias,
resulting from tendency to selectively publish results
that are statistically significant. However, this had prob-
ably little impact as there was no evidence of funnel
plot asymmetry. In addition, most studies reported a
non-significant effect, which makes publication bias
highly unlikely.
Currently available vaccines targeting HPV types 16
and 18, accounting for 70% of cervical cancers world-
wide, opened up new avenues in prevention of this
important public health problem. If a longitudinal pro-
spective study shows a cause - effect model, than it is
clear that greater attention needs to be given to BV in
the global fight against HPV infection and women with
BV should be considered a priority group for prophylac-
tic vaccination. Cervical screening remains of course a
major preventive focus for the cancer control program. If
BV is a risk factor for cervical HPV acquisition, it is clear
that screening guidelines must adapt and implement a
sensitive tool like HPV DNA testing in primary screening
in BV-positive women, instead of cytological testing.
Closer follow-up of these patients should be considered.
Restoring the vaginal microflora should in that case be a
promising answer to the high prevalence of HPV infec-
tions. Randomized clinical trials to determine effect of
BV control measures on HPV acquisition may then be
worth considering. In addition to the need to evaluate
the potential of BV treatment to prevent HPV acquisition
and transmission, a better understanding of its risk
factors and determinants of recurrence is required.
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Conclusion
This meta-analysis suggests a positive association
between BV and cervical HPV infection. Considering
that these conditions are very common among women
worldwide, further research in this field is imperative.
More data from prospective studies are needed to accu-
rately evaluate temporal sequence of acquisition of both
conditions in any attempt to determine a causal rela-
tionship and to identify specific sub-populations with a
stronger association between BV and HPV.
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